4.7 Review

Therapy for persistent HIV

Journal

TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 31, Issue 5, Pages 206-211

Publisher

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2010.02.001

Keywords

-

Funding

  1. National Institutes of Health [RO1 AI045297, U19AI082608, T32 AI 07001-33]
  2. Merck Research Laboratories
  3. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007001, U19AI082608, R01AI045297, R34AI084553] Funding Source: NIH RePORTER
  4. NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH085597] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Given the scope of the human immunodeficiency virus (HIV) pandemic, millions of people will need of chronic antiretroviral therapy (ART) for decades into the future. It is hoped that progress in prevention of HIV infection can be made, but there have been few successes in this effort thus far. ART also presents formidable problems. Therefore, research must continue on improvements in prevention and treatment, but future HIV research should now also seek to develop temporally contained therapies capable of eradicating HIV infection. This review will explore what is known about the mechanisms that restrain HIV expression and result in persistent, latent proviral infection, and what these mechanisms tell us about potential approaches towards eradication of HIV infection.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available